



Neuromed President & CEO Dr. Christopher Gallen named “100 Most Inspiring People in the Life Sciences Industry”

VANCOUVER, BC and CONSHOHOCKEN, PA – June 19, 2007 – Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, is pleased to announce its President & CEO, Dr. Christopher Gallen has been recognized as one of the “100 Most Inspiring People in the Life Sciences Industry” as voted by readers of PharmaVOICE magazine. Dr. Gallen will be featured, along with other recipients, in the July/August issue of PharmaVOICE magazine (<http://www.pharmavoice.com/>).

Recognition of this title was given to executives who viewed industry trends as challenges not burdens, as opportunities not obstacles. Winners were also selected for their passion and conviction, innovation and ability to think outside the box and develop breakthrough strategies, products, and services; for pioneering new paths and lifting their companies to new heights and for mentoring the next generation of industry leaders.

About Christopher C. Gallen, MD, PhD

Dr. Gallen joined Neuromed in July 2004 as President & CEO and has led the company to two of its private equity financings, a transformative licensing deal with Merck & Co. and an acquisition of the U.S. marketing rights of a Phase 3 chronic pain product from ALZA Corporation. Dr. Gallen has extensive experience in clinical and corporate development and has been instrumental in the commercialization of several drugs. Most recently, Dr. Gallen was Vice President and Chief of Operations, Clinical Research and Development at Wyeth Research in charge of global clinical operations including clinical trial management, data management, biostatistics, clinical communications, procedural compliance and training and was a key driver in the re-engineering of Wyeth Clinical Research and Development. Prior to Wyeth, Dr. Gallen was VP of Clinical Research at Pharmacia and was responsible for overseeing global CNS development and clinical operations for all specialties and clinical research in the Western Hemisphere. Previous positions include President of the CRO division at Premier Research Worldwide, where he was a key contributor to a successful IPO, and Senior Director of Medical and Scientific Services at Quintiles International Clinical Research Corporation. Dr. Gallen received his M.D. and Ph.D. (Biochemistry) from the Emory University School of Medicine in Atlanta, Georgia and completed residencies in Psychiatry at Stanford and in Neurology at UCSD.

About Neuromed

Neuromed is a privately held biopharmaceutical company in business to develop safer and more effective pain drugs. We are combining our pharmaceutical expertise in research, development and commercialization to improve existing pain treatments as well as develop new pain medicines. For more information visit www.neuromed.com.

###

For more information regarding this press release, contact:

Julie Jang
Manager, Communications
Neuromed Pharmaceuticals
Phone: (604) 909-2547
Email: jjang@neuromed.com